Available Now

A clear path forward: the latest innovation in kidney transplant surveillance can drive better outcomes for your patients

AlloSure is the first and only non-invasive test which assesses organ health by directly measuring allograft injury.

AlloSure is a clinically and analytically validated, non-invasive blood test that measures donor-derived cell-free DNA (dd-cfDNA), an indicator of kidney injury.

AlloSure can accurately determine active rejection, enabling better management of your kidney transplant patients.

 

Cell-free DNA: a clear biomarker

Cell-Free DNA (cfDNA) is fragmented DNA in the bloodstream that originates from cells undergoing cell injury and death.

When graft injury occurs, donor-derived cell-free DNA (dd-cfDNA) increases in the blood.

AlloSure accurately measures dd-cfDNA  and is a powerful, non-invasive tool for kidney transplant surveillance.

Screen Shot 2017-07-26 at 4.50.55 PM

 

Put your patients on a clear path forward with AlloSure

Features:

  • Measures donor-derived cfDNA, a direct indicator of kidney injury
  • Clinically and analytically validated
  • More accurate than serum creatinine in diagnosis of active rejection
  • Does not require donor or recipient genotyping
  • Appropriate for a wide array of patients who are 2 weeks or more post transplant and 18+ years of age
  • Will be covered by Medicare at launch

References

1 Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18:890-902
2 Bloom RD., Bromberg JS, Poggio E, et al. Cell-free DNA and active rejection in kidney allografts. J Am SocNephrol. 2017.
3 Bromberg JS, Brennan DC, Poggio E, et al. Biological variation of donor-derived cell-free DNA in renal transplant recipients: clinical implications. J Appl Lab Med. 2017;1(5).